Fucosidosis therapy — the ultra-rare lysosomal storage disorder caused by FUCA1 gene mutations resulting in alpha-L-fucosidase deficiency, with fewer than 200 documented cases worldwide and no FDA-approved disease-modifying treatment — represents the most underserved orphan disease market, with the Fucosidosis Therapeutic Market reflecting the critical unmet need driving gene...